The benefits and challenges associated with the use of drug delivery systems in cancer therapy

被引:132
作者
Cukierman, Edna [1 ]
Khan, David R. [2 ]
机构
[1] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA
[2] W Texas A&M Univ, Dept Math Chem & Phys, Canyon, TX 79016 USA
关键词
Liposomes; Micelles; Extracellular matrix; Drug delivery; Chemotherapy; Tumor microenvironment; Nanocarriers; CHONDROITIN SULFATE PROTEOGLYCAN; MELANOMA-CELL MOTILITY; EXTRACELLULAR-MATRIX; LIPOSOMAL DOXORUBICIN; POLYMERIC MICELLES; BREAST-CANCER; IN-VIVO; TUMOR MICROENVIRONMENT; TARGETED DELIVERY; INDUCED APOPTOSIS;
D O I
10.1016/j.bcp.2010.04.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of drug delivery systems as nanocarriers for chemotherapeutic agents can improve the pharmacological properties of drugs by altering drug pharmacokinetics and biodistribution. Among the many drug delivery systems available, both micelles and liposomes have gained the most attention in recent years due to their clinical success. There are several formulations of these nanocarrier systems in various stages of clinical trials, as well as currently clinically approved liposomal-based drugs. In this review, we discuss these drug carrier systems, as well as current efforts that are being made in order to further improve their delivery efficacy through the incorporation of targeting ligands. In addition, this review discusses aspects of drug resistance attributed to the remodeling of the extracellular matrix that occurs during tumor development and progression, as well as to the acidic, hypoxic, and glucose-deprived tumor microenvironment. Finally, we address future prospective approaches to overcoming drug resistance by further modifications made to these drug delivery systems, as well as the possibility of coencapsulation/coadministration of various drugs aimed to surmount some of these microenvironmental-influenced obstacles for efficacious drug delivery in chemotherapy. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:762 / 770
页数:9
相关论文
共 113 条
[31]   A CELL-SURFACE CHONDROITIN SULFATE PROTEOGLYCAN, IMMUNOLOGICALLY RELATED TO CD44, IS INVOLVED IN TYPE-I COLLAGEN-MEDIATED MELANOMA CELL MOTILITY AND INVASION [J].
FAASSEN, AE ;
SCHRAGER, JA ;
KLEIN, DJ ;
OEGEMA, TR ;
COUCHMAN, JR ;
MCCARTHY, JB .
JOURNAL OF CELL BIOLOGY, 1992, 116 (02) :521-531
[32]   Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy [J].
Gabizon, AA .
CANCER INVESTIGATION, 2001, 19 (04) :424-436
[33]  
Gabizon AA, 2001, CLIN CANCER RES, V7, P223
[34]   Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia [J].
Gandara, DR ;
Lara, PN ;
Goldberg, Z ;
Le, QT ;
Mack, PC ;
Lau, DHM ;
Gumerlock, PH .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :102-109
[35]   Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics [J].
Gerweck, LE ;
Vijayappa, S ;
Kozin, S .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) :1275-1279
[36]   Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging [J].
Ghajar, Cyrus M. ;
Bissell, Mina J. .
HISTOCHEMISTRY AND CELL BIOLOGY, 2008, 130 (06) :1105-1118
[37]   Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers [J].
Gillies, ER ;
Jonsson, TB ;
Fréchet, JMJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (38) :11936-11943
[38]   pH-responsive copolymer assemblies for controlled release of doxorubicin [J].
Gillies, ER ;
Fréchet, JMJ .
BIOCONJUGATE CHEMISTRY, 2005, 16 (02) :361-368
[39]   Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIα protein levels and decreasing sensitivity to topoisomerase-targeted drugs [J].
Gray, MD ;
Mann, M ;
Nitiss, JL ;
Hendershot, LM .
MOLECULAR PHARMACOLOGY, 2005, 68 (06) :1699-1707
[40]   The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis [J].
Greijer, AE ;
van der Wall, E .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (10) :1009-1014